CN102784152B - Application of tanshinone IIA in reduction of arsenic content in body blood - Google Patents

Application of tanshinone IIA in reduction of arsenic content in body blood Download PDF

Info

Publication number
CN102784152B
CN102784152B CN201110132465.9A CN201110132465A CN102784152B CN 102784152 B CN102784152 B CN 102784152B CN 201110132465 A CN201110132465 A CN 201110132465A CN 102784152 B CN102784152 B CN 102784152B
Authority
CN
China
Prior art keywords
arsenic
tanshinone iia
tanshinone
blood
iia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201110132465.9A
Other languages
Chinese (zh)
Other versions
CN102784152A (en
Inventor
李禄金
盛玉成
杨娟
石劲敏
许羚
王鲲
何迎春
陈君超
吕映华
郑青山
刘红霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai University of Traditional Chinese Medicine
Original Assignee
Shanghai University of Traditional Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai University of Traditional Chinese Medicine filed Critical Shanghai University of Traditional Chinese Medicine
Priority to CN201110132465.9A priority Critical patent/CN102784152B/en
Publication of CN102784152A publication Critical patent/CN102784152A/en
Application granted granted Critical
Publication of CN102784152B publication Critical patent/CN102784152B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a new application of tanshinone IIA. Tanshinone IIA is one of main effective components in tanshinone, has a quinoid structure, is easy to be oxidized and reduced, can participate in various biochemical reactions in human body and has various biological activities. Tanshinone IIA has various pharmacological effects, can resist cardiac muscle acute hypoxic injury, resist arrhythmia, improve blood vessel smooth muscle functions, and has protection effect on tissue damage caused by ischemia-reperfusion. According to the invention, tanshinone IIA can reduce the arsenic content in body blood. Arsenic is a toxic substance with severe harm to human body. Research shows that when compared with a blank control group, rats administrated with tanshinone IIA have obviously reduced arsenic concentration in blood.

Description

Tanshinone IIA is the purposes in arsenic content in reducing body blood
Technical field:
The invention belongs to medical technical field, be specifically related to tanshinone ⅡA effect in arsenic content in reducing body blood.
Background technology:
Arsenic is present in nature widely, in industrial and agricultural production application quite wide, be a kind of toxicant that body is had to serious harm.Arsenic is protoplasm poisonous substance, its with histiocyte endoenzyme be easily in sulfydryl be combined, thereby the activity of inhibitory enzyme, cause cellular metabolism obstacle, the toxicity of formation to central nervous system, cardiovascular system, gastronintestinal system, causes that oral cavity, esophagus, gastric mucosal erosion, swelling are hemorrhage, toxic hepatitis, subacute severe hepatitis, heart fat infiltration, central nervous system's anoxia, glomerular injury etc.In recent years, endemic arsenic poisoning is more serious both at home and abroad, in China's animal husbandry, be still widely used organo-arsenic as feed additive (growth promoter), cause common food (animality and vegetalitas) all can detect arsenic, especially with marine product for the highest, as the mankind of food chain terminal, unavoidably there is in vivo certain arsenic especially and accumulate.At present, about the Therapeutic Method of arseniasis, mainly contain selenium supplement treatment, with sulfydryl, drive arsenic treatment and utilize treatment by Chinese herbs etc., but up to now, without any medicine, any therapy, obtain satisfied row's arsenic curative effect.Therefore, finding effectively medicine or the therapy of row's arsenic is a urgent task.
Summary of the invention:
Radix Salviae Miltiorrhizae is the root of Labiatae salvia, and TANSHINONES is the composition in the ether extract of salviamiltiorrhizabung root, is the main effectively site of action of Radix Salviae Miltiorrhizae.Tanshinone ⅡA is one of main effective ingredient in TANSHINONES, is fat-soluble cherry red acicular crystal.Tanshinone ⅡA molecular formula is C 19h 18o 3, relative molecular mass is 294.33, and it contains quinoid structure, and easy oxidized reduction can participate in the multiple biochemical reaction of body and have multiple biological activity.Tanshinone ⅡA has multiple pharmacological effect, can resist myocardium acute anoxia damage, arrhythmia, improve vascular smooth muscle function, and the tissue injury that ischemia-reperfusion is caused has protective effect.Tanshinone ⅡA is by the mechanism performance antitumor action that kills and wounds, induces differentiation and apoptosis, anti-invasion and transfer to tumor cell.Tanshinone ⅡA also has neuroprotective, significant to nervous system disease control.
In the present invention, will for tanshinone ⅡA, provide a new purposes, while using separately, have blood arsenic content in obvious reduction body.
Accompanying drawing explanation: Fig. 1 is blank group and the average whole blood arsenic concentration-time plot of tanshinone ⅡA suspension oral gavage group rat (n=12)
The specific embodiment:
One materials and methods
1.1 laboratory animal
Laboratory animal adopts male Sprague-Dawley rat, and male, body weight 320g~370g, is provided by Shanghai Slac Experimental Animal Co., Ltd., and production licence number is SCXK (Shanghai) 2007-0005.
Feeding environment is regular grade experimental animal room, temperature: 22 ℃~23 ℃, and relative humidity 40%~70%, occupancy permit number is SCXK (Shanghai) 2006-0003.
1.2 medicines and reagent
(1) As standard inventory solution 1gL -1(As standard stock solution, 1gL -1): Merck company provides, lot number HC 961324;
(2) nitric acid (Nitric acid): HPLC level, Merck company, lot number K40748356004;
(3) hydrochloric acid (Hydrochloride acid): HPLC level, Merck company, lot number K39343417841;
(4) Fluohydric acid. (Hydrofluoric acid): top grade is pure, and Chemical Reagent Co., Ltd., Sinopharm Group provides, lot number 20100520;
(5) high-purity helium (99.999%): Shanghai success gas company limited provides;
(6) tanshinone ⅡA raw material: purity 98%, lot number SR20100518, Xin Rui bio tech ltd, Shaanxi provides;
(7) sodium carboxymethyl cellulose (Carboxymethylcellulose sodium, CMC): Chemical Reagent Co., Ltd., Sinopharm Group provides, lot number 20100520;
(8) ultra-pure water (purified water): Millipore A10 ultra-pure water instrument preparation;
1.3 reagent preparations
(1) preparation of arsenic series standard solution
ICP-AES arsenic standard solution: precision measures As standard inventory solution (1gL -1) 0.25mL, add in 50mL volumetric flask, with deionized water, be assigned to scale, obtain 5mgL -1arsenic standard solution; Precision measures As standard inventory solution 0.05mL, adds in 50mL volumetric flask, with deionized water, is assigned to scale, obtains 1mgL -1arsenic standard solution; Precision measures 5mgL -1arsenic standard solution 5mL, add in 50mL volumetric flask, with deionized water, be assigned to scale, obtain 0.5mgL -1arsenic standard solution; Precision measures 1mgL -1arsenic standard solution 5mL, add in 50mL volumetric flask, with deionized water, be assigned to scale, obtain 0.1mgL -1(100 μ gL -1) arsenic standard solution.
Precision measures above-mentioned 100 μ gL -1arsenic standard solution 25mL, add in 50mL volumetric flask, with deionized water, be assigned to scale, obtain 50 μ gL -1arsenic standard solution; Precision measures 50 μ gL -1arsenic standard solution 20mL, add in 50mL volumetric flask, with deionized water, be assigned to scale, obtain 20 μ gL -1arsenic standard solution; Precision measures 20 μ gL -1arsenic standard solution 25mL, add in 50mL volumetric flask, with deionized water, be assigned to scale, obtain 10 μ gL -1arsenic standard solution; Precision measures 10 μ gL -1arsenic standard solution 25mL, add in 50mL volumetric flask, with deionized water, be assigned to scale, obtain 5 μ gL -1arsenic standard solution; Precision measures 5 μ gL -1arsenic standard solution 10mL, add in 50mL volumetric flask, with deionized water, be assigned to scale, obtain 1 μ gL -1arsenic standard solution.
The preparation of (2) 0.5% carboxymethylcellulose sodium solutions
Accurately take the sodium carboxymethyl cellulose powder of 5.00g, put in 800ml beaker, add 500ml distilled water, 60 ℃ of magnetic agitation 4h, are transferred in 1000ml volumetric flask, are settled to scale.4 ℃ store for future use.
(3) preparation of medicine suspension
Tanshinone ⅡA suspension: precision takes tanshinone ⅡA 51.0mg, grinds to form fine powder, slowly adds a small amount of 0.5%CMC solution, continue to be ground to evenly, be transferred in 25mL tool plug graduated cylinder, repeatedly shift and merge, add to 25mL, be mixed with the suspension that concentration is 2gL-1.Face and join existing use.
1.4 instrument
(1) U.S. Perkin Elmer OPTIMA-DV of company 5300 type inductance couplings and plasma emission spectrometer (ICP-AES);
(2) 7500Ce of U.S. Agilent company inductance coupling and plasma mass spectrograph (ICP-MS);
(3) one of German Saturious BT2202S percentage analytical balance (taking blood sample);
(4) the rich fast experiment SSW of the company limited type electric heating constant temperature tank in Shanghai;
(5) Switzerland Mettler Toledo AL204-IC precision balance (taking raw material);
(6) Switzerland Mettler Toledo XP-205DU 100,000/precision balance (taking reference substance)
1.5 instrument settings
(1) ICP-AES instrumental method arranges
Instrument working parameter: RF power 1300w, nebulizer flow 0.8Lmin -1, assisted gas flow 0.2Lmin -1, plasma gas flow rate 15Lmin -1, peristaltic pump flow velocity 15mLmin -1, the time of integration 1~20s, analytical wavelengths 118.979nm.
(2) ICP-MS instrumental method arranges
Instrument working parameter: radio-frequency power 1500w; Sampling depth 8.0mm; Carrier gas flux 0.7Lmin-1; Assisted gas flow 0.2Lmin-1; Plasma gas flow rate 15Lmin-1; Reaction gas helium; 2 ℃ of S/C temperature; Sample hoisting velocity 0.5rps; The high salt type of nebulizer: Babington; Sampling spiroid type and diameter: nickel cone, 0.8mm; Intercepting cone type and diameter: nickel cone, 0.4mm; Drainage pattern: Spectrum; Count/quality: 3; Number of repetition: 3; Detection mode: automatically; Analytical wavelengths 118.979nm.
1.6 EXPERIMENTAL DESIGN
Choose 12 rats, non-fasting, body weight is (342.8 ± 11.4) g, be divided at random 2 groups, every group before administration and after administration 0.25,0.5,0.75,1,2,3,4,6,8,10,12,24,32,48,56,72,80,96,104,120,144h rat eye socket venous plexus gather anticoagulated whole blood 0.5mL, preserve until analyze for-40 ℃.
The administration arrangement of the different groups of table 1-1
Figure GSB00000590728800041
1.7 containing arsenic sample pretreatment
Precision takes rat whole blood 0.5g to be measured in brand-new gas phase head space bottle, adds 4mL nitric acid, 1mL hydrochloric acid and 0.5mL Fluohydric acid., seals.Be positioned in 50 ℃ of water-baths and be incubated overnight.Second day is uncapped sample in head space bottle is transferred in the brand-new Falcon pipe of 15mL, and repeatedly rinse merges all liq and adds water to 15g.The centrifugal 10min of 4000rpm, gets supernatant 6mL sample introduction ICP-AES or ICP-MS and analyzes.
1.8 date processing and statistics
AUC 0-t(area under 0-144h blood arsenic-time graph) adopts statistical moment to calculate.Between two groups, AUC0-t, difference adopt SNK check (q check), by SAS 9.1.3, are realized.
Two results
1. arsenic standard curve
ICP-AES: standard curve was former point curve, concentration is respectively 0,0.1,0.5,1,5mgL -1, regression equation is that the range of linearity is 0~5mgL -1.
ICP-MS: standard curve was former point curve, concentration is respectively 0,1,2,5,10,20,50,100 μ gL -1, regression equation is Y=7.035e-3*X-2.813e-4, the range of linearity is 0~100 μ gL -1.
2. Pharmacokinetics in Rat
Blank group rat whole blood arsenic concentration is in Table 2-1, and the whole blood arsenic concentration after gavage drug suspension is in Table 2-2, two groups of AUC 0-tbetween value and group, comparative result is in Table 2-3.Use tanshinone ⅡA can make the AUC of blood arsenic 0-tsignificantly decline.
Total arsenic concentration (the mgL of whole blood of the blank group of table 2-1 rat -1)
Figure GSB00000590728800051
Table 2-2 rat oral gavage tanshinone ⅡA (50mgkg -1) after the total arsenic concentration (mgL of whole blood -1)
Figure GSB00000590728800061
The blood arsenic AUC of the different groups of table 2-3 0-t
Figure GSB00000590728800062
Note: " * " and blank group be P < 0.05 relatively

Claims (1)

1. tanshinone ⅡA is for the preparation of the purposes of the medicine of the content of the heavy metal arsenic in reduction blood.
CN201110132465.9A 2011-05-20 2011-05-20 Application of tanshinone IIA in reduction of arsenic content in body blood Expired - Fee Related CN102784152B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201110132465.9A CN102784152B (en) 2011-05-20 2011-05-20 Application of tanshinone IIA in reduction of arsenic content in body blood

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201110132465.9A CN102784152B (en) 2011-05-20 2011-05-20 Application of tanshinone IIA in reduction of arsenic content in body blood

Publications (2)

Publication Number Publication Date
CN102784152A CN102784152A (en) 2012-11-21
CN102784152B true CN102784152B (en) 2014-04-09

Family

ID=47149873

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201110132465.9A Expired - Fee Related CN102784152B (en) 2011-05-20 2011-05-20 Application of tanshinone IIA in reduction of arsenic content in body blood

Country Status (1)

Country Link
CN (1) CN102784152B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101890042A (en) * 2009-05-18 2010-11-24 上海交通大学医学院附属瑞金医院 Chinese medicinal compound preparation arsenic tetrasulfide-tanshinone-indirubin and preparation method thereof and application thereof in preparing antineoplastic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101890042A (en) * 2009-05-18 2010-11-24 上海交通大学医学院附属瑞金医院 Chinese medicinal compound preparation arsenic tetrasulfide-tanshinone-indirubin and preparation method thereof and application thereof in preparing antineoplastic agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia;Lan Wang等;《Proceedings of the national academy of sciences》;20080325;第105卷(第12期);4826-4831 *
Lan Wang等.Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia.《Proceedings of the national academy of sciences》.2008,第105卷(第12期),4826-4831.

Also Published As

Publication number Publication date
CN102784152A (en) 2012-11-21

Similar Documents

Publication Publication Date Title
CN102784140B (en) Application of indirubin in reduction of arsenic content in body blood
CN102784152B (en) Application of tanshinone IIA in reduction of arsenic content in body blood
CN102078317A (en) Dihydroartemisinine-phospholipid complex and preparation and application thereof
CN102784151B (en) Application of combination of tanshinone IIA with indirubin in reduction of arsenic content in body blood
CN101234122B (en) New purpose of polylysine
CN103638052A (en) Polyrhachis dives extractive, and preparation and medical purpose thereof
CN102743376A (en) Costustoot pharmaceutical composition and medicinal application
CN102526081A (en) Medicinal composition capable of inhibiting proliferation of tumor cells
CN102579428B (en) Application of tetranor-diterpene dilactone derivatives in preparing anticancer drug
CN100515461C (en) Gamboge soft paste preparation
CN106420707A (en) Application of Linderolide H in preparing medicine for treating carcinoma of uterine cervix
CN106420708A (en) Application of Linderolide H in preparation of medicine for treating skin cancer
CN103463032B (en) Application of Lycojaponicumin A in preparation of pancreatic cancer treatment drug
CN106491588A (en) Applications of the Linderolide H in treatment bladder cancer drug is prepared
CN102872010B (en) Application of Aphanamixoid A in drugs for treating ovarian cancer
CN102861096B (en) Application of Houttuynoid E in preparing medicine for treating cervical cancer
CN103405416B (en) The application of Chukrasone B in preparation treatment endometrial cancer drug
CN103405444B (en) The application of Chukrasone A in preparation treatment bladder cancer medicine
CN103405406B (en) The application of a kind of compound in preparation treatment endometrial cancer drug
CN103463051B (en) The application of Lycojaponicumin A in preparation treatment medicine for nasopharyngeal
CN103463058B (en) The application of Lycojaponicumin A in treatment cancer of biliary duct medicine
CN103463045B (en) The application of Lycojaponicumin A in preparation treatment blindgut cancer
CN102872142B (en) Application of Houttuynoid D in drug for treating ovarian cancer
CN103316008A (en) Application of Aspeverin in preparation of medicine for treating rectal cancer
CN113577058A (en) Application of pyrone compound in preparation of lung cancer chemotherapy sensitization drug and drug

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140409

Termination date: 20200520